Drug Profile
PXS 5338K
Alternative Names: PXS-5338; PXS-5338KLatest Information Update: 13 Dec 2023
Price :
$50
*
At a glance
- Originator Pharmaxis
- Developer Synairgen; Syntara Limited
- Class Antifibrotics; Antineoplastics; Pyrans; Small molecules
- Mechanism of Action LOXL2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer; Hepatic fibrosis; Non-alcoholic steatohepatitis; Pulmonary fibrosis; Renal fibrosis
Most Recent Events
- 04 Dec 2023 Pharmaxis is now called Syntara Limited
- 28 Jul 2021 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis(In volunteers) in Australia (PO, Capsule)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Hepatic-fibrosis in Australia (PO)